NIPT in India: Cost, Accuracy, and What It Can (and Can't) Tell You

• NIPT is a screening test, not a diagnostic one. A high-risk result needs confirmation with CVS or amniocentesis before any pregnancy decision.
• It is done from 10 weeks onwards, needs only a blood draw from your arm, and carries no miscarriage risk.
• Accuracy is highest for Down syndrome (trisomy 21, around 99 percent detection), high for trisomies 18 and 13, lower for sex chromosome and microdeletion panels.
• A basic trisomy 21/18/13 panel costs roughly 12,000 to 18,000 rupees; extended panels reach 28,000 to 35,000 rupees. Most Indian families pay out of pocket.
• NIPT does not replace the 18 to 20 week anomaly scan, and it does not screen for structural defects, single-gene disorders like thalassaemia, or anything outside its panel.
• Under the PC-PNDT Act, compliant Indian labs redact fetal sex from the report. No prenatal test will legally tell you the baby's sex in India.

NIPT is a blood test taken from your arm — no needle goes anywhere near the womb. From around 5 weeks of pregnancy, tiny fragments of DNA from the placenta start circulating in your blood. By 10 weeks the fraction is usually high enough (about 4 percent or more) for a lab to separate out those fetal fragments, count the chromosomes within them, and report whether the count for chromosome 21, 18 or 13 looks normal or shows an extra copy.

Because the placenta carries the same DNA as the baby in almost all cases, reading placental fragments is a very good proxy for reading the baby's chromosomes. That is the whole idea behind "cell-free fetal DNA" testing.

Older serum screens like the double or triple marker measure hormone levels (PAPP-A, hCG, AFP, estriol, inhibin-A) and combine them with your age and NT scan measurements to estimate a statistical risk. That is an indirect calculation. NIPT is a direct read of the actual fetal DNA, which is why its accuracy is so much higher than the dual marker and NT scan combination.

What NIPT does not do is sample fetal cells themselves — it reads DNA fragments only, and only for a defined set of chromosomes (typically 21, 18, 13 and the sex chromosomes, with optional microdeletion add-ons). It cannot see structural defects of the heart, brain or spine (those show up on the 18 to 20 week anomaly scan), cannot detect single-gene conditions like Thalassemia Carrier Screening for Indian Couples, and cannot tell you anything about chromosomes outside its panel. For help reading a typical Indian scan and lab report alongside NIPT, see our guide to understanding scans, labs and reports.

The earliest reliable window is 10 weeks of pregnancy, counted from the first day of your last period and ideally confirmed on the dating scan. Before 10 weeks the fetal DNA fraction is often too low — a sample drawn at 8 or 9 weeks can come back as a "no-call" (the lab cannot give a result and a repeat is needed) or, rarely, be falsely reassuring.

From 10 weeks onwards NIPT performs well through the rest of pregnancy. In practice most women who choose it test between 10 and 14 weeks, so that any abnormal result still leaves time for early diagnostic confirmation with CVS or Amniocentesis in India: When It's Needed, Risks, Results & NIPT.

NIPT is most strongly indicated when the chance of a chromosomal condition is higher than the general population baseline:

It is also increasingly chosen electively by women with no specific risk factor, simply for the reassurance of an early, high-accuracy screen — particularly by those who would prefer to avoid amniocentesis unless a clear high-risk result demands it. That is a valid choice. So is the opposite: some couples prefer no chromosomal screening at all because they would continue the pregnancy regardless. Screening should never be presented as automatic. For where this sits in the wider antenatal timeline, see what to expect week by week.

The headline figure — around 99 percent — is specifically the detection rate for Down syndrome (trisomy 21) in singleton pregnancies. That number is honest for trisomy 21, and it is meaningfully higher than the 80 to 85 percent of the double marker, the roughly 70 percent of the triple marker, or the 80 to 85 percent of the quadruple marker. NIPT also has a much lower false-positive rate (about 0.1 percent for trisomy 21), which means far fewer women are sent for an unnecessary amniocentesis on the basis of a falsely high-risk screen.

For other conditions on the standard panel, accuracy is still high but slightly lower. Detection of trisomy 18 is around 97 percent and trisomy 13 around 90 percent. Sex chromosome variations (Turner 45,X; Klinefelter 47,XXY; triple X 47,XXX; XYY) are detected at 90 to 95 percent but with somewhat higher false-positive rates, partly because your own DNA can carry sex chromosome variations that confuse the read.

Microdeletion panels — small missing pieces of specific chromosomes, such as the 22q11 deletion (DiGeorge syndrome) — vary widely. Published detection rates are lower and false-positive rates much higher, which is why many labs and clinicians offer these add-ons cautiously, with explicit counselling that a positive microdeletion result is far more likely to be a false alarm than for the main trisomies.

Some technical situations can produce a no-call or an unreliable result: maternal obesity (the fetal DNA fraction is diluted in a larger blood volume), very early gestation, low fetal fraction for unknown reasons, vanishing twin syndrome where a lost twin's DNA confuses the read, certain maternal medical conditions, and maternal chromosomal mosaicism. A no-call usually means a repeat sample a few weeks later or, if it persists, a discussion about going straight to a diagnostic test. A prenatal genetic counsellor can help you weigh these options.

This is the single most important thing to understand about NIPT. It is a screening test, not a diagnostic one. A high-risk result does not mean the baby has the condition — it means the probability is high enough that the next step is offered: a diagnostic test (CVS or amniocentesis) that actually samples fetal cells and gives a definitive yes or no. The false-positive rate for trisomy 21 is low at around 0.1 percent, but at the population level that still translates into real numbers of women who get a high-risk NIPT and a completely normal amniocentesis.

Equally, a low-risk result is reassuring but not a guarantee. It tells you the specific conditions on the panel are unlikely; it says nothing about conditions outside the panel, structural defects of the heart, brain, kidneys or spine, single-gene disorders, or problems that develop later in pregnancy. The anomaly scan at 18 to 20 weeks still needs to happen, third-trimester growth scans still need to happen, and routine antenatal care continues exactly as in any pregnancy.

The clinical pathway for an abnormal NIPT in India is fairly standard: a counselling visit (with a genetic counsellor if the lab has one, otherwise with your OB-GYN), an explanation of what the specific result actually means in terms of probability, and an offer of CVS at 11 to 14 weeks or amniocentesis from 16 weeks for definitive confirmation. Any decision about continuing or ending the pregnancy is made only after diagnostic confirmation, and within the Medical Termination of Pregnancy Act framework — never on a screening result alone.

Several NIPT panels are available through Indian labs, marketed under international brand names (Verifi, PrenaTest, MaterniT21, IriSure) and under lab-specific indigenous names. The actual sequencing is done either in an Indian central lab (Thyrocare, Metropolis, SRL Diagnostics, Dr Lal PathLabs and a few others run their own facilities) or shipped overseas, with results returned in 7 to 14 days either way.

Cost varies by lab, panel size and city. The basic panel covering trisomy 21, 18 and 13 is usually priced around 12,000 to 18,000 rupees. Adding the sex chromosome panel takes it to roughly 15,000 to 22,000 rupees. Extended panels with select microdeletions sit in the 22,000 to 30,000 rupee range, and premium whole-genome or whole-chromosome panels can reach 28,000 to 35,000 rupees. Twin pregnancy NIPT is priced higher and usually with reduced microdeletion coverage, because the analysis is more complex.

Insurance coverage is inconsistent. NIPT is usually not covered by basic health policies unless the pregnancy is documented as High-Risk Pregnancy in India: Criteria, Care and What It Means — for example with an abnormal NT scan, a high-risk marker result, advanced maternal age, or a previous chromosomal pregnancy. Even where coverage exists, prior authorisation is often required and reimbursement is partial. Most women in India still pay out of pocket.

When budgeting, it helps to know that the basic trisomy 21/18/13 panel captures most of the conditions that are clinically actionable. The more expensive extended panels add coverage for conditions where the test is less accurate and the decisions harder — so a bigger panel is not automatically a better one.

The Pre-Conception and Pre-Natal Diagnostic Techniques (PC-PNDT) Act, 1994, prohibits the disclosure of fetal sex by any prenatal technique, regardless of how the information is technically obtained. Because NIPT analyses the sex chromosomes as part of its standard panel, the test does, technically, identify fetal sex along the way. Compliant Indian labs handle this by redacting the sex chromosome read from the report released to parents — an abnormal sex chromosome aneuploidy is still flagged if present, but the specific male-or-female result is removed before the report is shared.

Choosing a PC-PNDT-compliant lab is not optional in India. A compliant lab is registered with the appropriate authority, requires a signed Form F for every NIPT request (a standard form documenting the indication, part of the audit trail), provides a report with no line referring to fetal sex, and works with an OB-GYN who is similarly registered. Any lab or doctor offering to reveal fetal sex through NIPT is breaking the law — and both the provider and the family requesting disclosure can face criminal penalties.

This is not just bureaucracy. The PC-PNDT Act exists because of decades of sex-selective abortion in parts of India, and the sex ratio at birth in some states remains skewed enough that the law is actively enforced. The clinical purpose of NIPT in India is chromosomal screening for medical conditions, not sex determination. If your reason for considering NIPT is to learn the baby's sex, the honest answer is that no test will legally provide that before birth, and NIPT is not a workaround. For the broader picture of how testing and law shape an Indian woman's pregnancy journey, see is my body ready to conceive and our calm guide to trying to conceive after 30.

NIPT costs a meaningful sum, and like any test it is only worth doing if the result would change something. If you would continue the pregnancy regardless — for personal, religious, family or other reasons — NIPT may not add value for you. That is a valid position, and declining screening is not a failure of antenatal care: the anomaly scan still happens, the rest of your care continues, and the absence of an NIPT result does not change the routine pathway.

There are also clinical situations where going directly to a diagnostic test is the better choice than screening first. If the NT scan at 11 to 13 weeks shows a markedly raised nuchal translucency (above 3.5 mm) or an absent nasal bone, or if a previous pregnancy had a confirmed chromosomal abnormality, the probability is high enough that CVS at 11 to 14 weeks gives a definitive answer faster than waiting for an NIPT and then needing CVS anyway. These decisions are best made with your OB-GYN, ideally with input from a maternal-fetal medicine specialist or genetic counsellor.

NIPT is also not the right test if your concern is a single-gene disorder (such as thalassaemia, sickle cell disease or cystic fibrosis), a structural defect, or a metabolic condition — those need targeted carrier testing, the anomaly scan, or specific gene panels rather than chromosomal screening. For the wider picture of how inherited conditions and birth defects are screened in India, see our guide to congenital diseases and birth defects. And if you have already had a pregnancy loss and are weighing the next pregnancy carefully, miscarriage: types, recovery and care in India covers the context in which these decisions sit.

The practical sequence is straightforward. You visit the lab or collection centre, a single tube of blood is drawn from your arm (the same as any routine blood test, no fasting needed), and the sample is shipped to the sequencing facility. Sequencing and bioinformatics take a few days, quality checks and report generation take a few more, and the report is released to your OB-GYN somewhere between day 7 and day 14. Some labs include a free or paid genetic counselling session with the report.

A low-risk result is reassuring — it needs no further action, and the rest of antenatal care continues as planned. A high-risk result triggers a structured pathway: a counselling visit to explain what the specific result means in terms of probability (not certainty), an offer of diagnostic confirmation with CVS or amniocentesis, and time and space to decide whether to pursue it. No major decisions about the pregnancy are made on the screening result alone.

A no-call result — where the lab cannot give a clear answer, often because the fetal fraction is too low — usually means a repeat blood sample a few weeks later. If the no-call persists across two samples, the conversation usually shifts to either accepting a non-result or moving directly to a diagnostic test if the underlying clinical concern is high enough.

NIPT is a planned, non-urgent screening test, so most conversations about it happen calmly at a routine antenatal visit. Still, a few situations warrant prompt contact with your OB-GYN or a maternal-fetal medicine specialist:

And as a general rule: if anyone — a lab, an agent, a clinic — offers to tell you the baby's sex through NIPT or any other test, treat it as a red flag. It is illegal in India, and a provider willing to break that law may not be reliable about anything else.

NIPT is a genuinely useful tool in Indian obstetric practice. It is more accurate than the older serum markers for the conditions it screens for, it carries no procedural risk because it is just a blood draw, it can be done early, and it spares many women an unnecessary amniocentesis by reducing false-positive screening results. For women with a higher baseline chromosomal risk — advanced maternal age, an abnormal NT scan, a high-risk serum marker, a previous chromosomal pregnancy, IVF or Twin Pregnancy in India: Chorionicity, Monitoring and Delivery — the case for NIPT over the older screens is clear, and the cost usually justifies itself.

For women with a low baseline risk who want the reassurance of a high-accuracy early screen and can afford the out-of-pocket cost, NIPT is a reasonable elective choice. For women who would continue the pregnancy regardless of the result, NIPT may not add value over the standard double marker plus anomaly scan pathway — and that is a perfectly valid place to stop.

What NIPT is not is a replacement for the anomaly scan, a substitute for diagnostic confirmation after a high-risk result, a way to learn the baby's sex in India, or a guarantee of a healthy baby. Used within its actual capabilities — chromosomal screening for a defined panel, with PC-PNDT-compliant reporting, diagnostic confirmation for any abnormal result, and alongside the routine scans and care of any pregnancy — NIPT is one part of a complete antenatal plan, not the whole plan.

• ACOG Practice Bulletin: Screening for Fetal Chromosomal Abnormalities (American College of Obstetricians and Gynecologists)
• NHS: Screening for Down's, Edwards' and Patau's syndromes
• The PC-PNDT Act, 1994 — Ministry of Health and Family Welfare, Government of India
• ISPD Position Statement on cell-free DNA screening (International Society for Prenatal Diagnosis)
• WHO: Maternal, newborn, child and adolescent health — antenatal care